{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:15:09Z","timestamp":1792084509020,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-026-04996-5","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:16:55Z","timestamp":1768799815000},"page":"7901-7911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lifecycle regulation of narrow therapeutic index drugs: Chinese practices, international benchmarks, and optimization pathways"],"prefix":"10.1007","volume":"399","author":[{"given":"Xuelin","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"6","key":"4996_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/13876988.2024.2426878","volume":"26","author":"D B\u00e9land","year":"2024","unstructured":"B\u00e9land D, Marier P, Paquet M (2024) Subnational comparative policy analysis: institutions, methodology, and research agenda. J Comp Policy Anal Res Pract 26(6):553\u2013566. https:\/\/doi.org\/10.1080\/13876988.2024.2426878","journal-title":"J Comp Policy Anal Res Pract"},{"issue":"4","key":"4996_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/j.1875-9114.1995.tb04379.x","volume":"15","author":"LZ Benet","year":"1995","unstructured":"Benet LZ, Goyan JE (1995) Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy 15(4):433\u2013440","journal-title":"Pharmacotherapy"},{"key":"4996_CR3","volume-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics","author":"LaurenceL. Brunton","year":"2018","unstructured":"Brunton Laurence L., Knollmann Bj\u00f6rn C., Hilal-Dandan Randa (2018) Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics, 13th edn. McGraw-Hill Education, New York","edition":"13th edn"},{"issue":"13","key":"4996_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.13506\/j.cnki.jpr.2019.13.006","volume":"40","author":"ZD Chen","year":"2019","unstructured":"Chen ZD (2019) Diversity of narrow therapeutic index drugs and recommendations for safe medication use. Shanghai Pharm 40(13):29\u201335. https:\/\/doi.org\/10.13506\/j.cnki.jpr.2019.13.006","journal-title":"Shanghai Pharm"},{"issue":"10","key":"4996_CR5","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.12092\/j.issn.1009-2501.2019.10.016","volume":"24","author":"XP Chen","year":"2019","unstructured":"Chen XP, Hu CY, Zhang L (2019) Common narrow therapeutic index drugs and their bioequivalence evaluation status. Chin J Clin Pharmacol Ther 24(10):1188\u20131193. https:\/\/doi.org\/10.12092\/j.issn.1009-2501.2019.10.016","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"4996_CR6","unstructured":"EMA (2016) Sirolimus product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/sirolimus-coated-tablets-05-1-and-2-mg-oral-solution-1-mgml-product-specific-bioequivalence-guidance_en.pdf. Accessed 19 Jun 2025"},{"key":"4996_CR7","unstructured":"EMA (2020) Levothyroxine product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/levothyroxine-tablets-125-mcg-25-mcg-50-mcg-75-mcg-100-mcg-additional-strengths-200-mcg-product-specific_en.pdf. Accessed 19 Jun 2025"},{"key":"4996_CR8","unstructured":"EMA (2021) Acenocoumarol product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/draft-acenocoumarol-tablet-1-mg-4-mg-product-specific-bioequivalence-guidance-first-version_en.pdf. Accessed 19 Jun 2025"},{"key":"4996_CR9","unstructured":"EMA (2024) Fampridine product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/fampridine-prolonged-release-tablet-10-mg-product-specific-bioequivalence-guidance_en.pdf. Accessed 19 Jun 2025"},{"key":"4996_CR10","unstructured":"EMA (2025a) Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/colchicine-tablet-05-mg-and-1-mg-product-specific-bioequivalence-guidance_en.pdf. Accessed 19 Jun 2025"},{"key":"4996_CR11","unstructured":"EMA (2025b) Tacrolimus granules product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/tacrolimus-granules-oral-suspension-02-1-mg-product-specific-bioequivalence-guidance-revision-1_en.pdf. Accessed 19 Jun 2025"},{"key":"4996_CR12","unstructured":"EMA (2025c) Everolimus product-specific bioequivalence guidance. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/everolimus-tablets-05-mg-1-mg-2-5-mg-5-mg-7-5-mg-10-mg-product-specific-bioequivalence-guidance-revision-2_en.pdf. Accessed 19 Jun 2025"},{"key":"4996_CR13","unstructured":"FDA (1995) Guidance for Industry. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. https:\/\/www.fda.gov\/media\/70949\/download. Accessed 23 Jun 2025"},{"key":"4996_CR14","unstructured":"FDA (2017) FY2016 Regulatory Science Report: Narrow Therapeutic Index Drugs. https:\/\/www.fda.gov\/industry\/generic-drug-user-fee-amendments\/fy2016-regulatory-science-report-narrow-therapeutic-index-drugs. Accessed 19 Jun 2025"},{"key":"4996_CR15","unstructured":"FDA (2018) FY2015 Regulatory Science Research Report: Narrow Therapeutic Index Drugs. In: FDA. https:\/\/www.fda.gov\/industry\/generic-drug-user-fee-amendments\/fy2015-regulatory-science-research-report-narrow-therapeutic-index-drugs. Accessed 20 Jan 2025"},{"key":"4996_CR16","unstructured":"FDA (2022) Draft Guidance on Tacrolimus. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_210115.pdf. Accessed 23 Jun 2025"},{"key":"4996_CR17","unstructured":"FDA (2023) Questions and Answers Regarding Tacrolimus Oral Capsules (Generic of Prograf), Made by Accord Healthcare Inc. In: FDA. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/questions-and-answers-regarding-tacrolimus-oral-capsules-generic-prograf-made-accord-healthcare-inc. Accessed 23 Jun 2025"},{"key":"4996_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/DHPS.S256455","volume":"12","author":"K Gantar","year":"2020","unstructured":"Gantar K, \u0160kerget K, Mochkin I, Bajc A (2020) Meeting regulatory requirements for drugs with a narrow therapeutic index: bioequivalence studies of generic once-daily tacrolimus. DHPS 12:151\u2013160. https:\/\/doi.org\/10.2147\/DHPS.S256455","journal-title":"DHPS"},{"key":"4996_CR19","unstructured":"Health Canada (2012) Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects. In: Government of Canada. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/bioavailability-bioequivalence\/comparative-bioavailability-standards-formulations-used-systemic-effects.html. Accessed 19 Jun 2025"},{"issue":"17","key":"4996_CR20","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.13286\/j.1001-5213.2025.17.01","volume":"45","author":"Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association, Clinical Pharmacy Branch of Chinese Medical Association, Working Group of Chinese Expert Consensus on Clinical Application Management of Narrow Therapeutic Index Drugs","year":"2025","unstructured":"Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association, Clinical Pharmacy Branch of Chinese Medical Association, Working Group of Chinese Expert Consensus on Clinical Application Management of Narrow Therapeutic Index Drugs (2025) Expert consensus on clinical application management of narrow therapeutic index drugs in China. Chin Hosp Pharm J 45(17):1933\u20131946+2005. https:\/\/doi.org\/10.13286\/j.1001-5213.2025.17.01","journal-title":"Chin Hosp Pharm J"},{"issue":"3","key":"4996_CR21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.5530\/jyp.2018.10.70","volume":"10","author":"K Iyer","year":"2018","unstructured":"Iyer K, Dilipkumar N, Vasaya S, Pawar S, Diwan A (2018) Comparison of drug related problems associated with use of narrow therapeutic index drugs and other drugs in hospitalized patients. JYP 10(3):318\u2013321. https:\/\/doi.org\/10.5530\/jyp.2018.10.70","journal-title":"JYP"},{"issue":"5","key":"4996_CR22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0009-9236(98)90100-X","volume":"63","author":"G Levy","year":"1998","unstructured":"Levy G (1998) What are narrow therapeutic index drugs? Clin Pharmacol Ther 63(5):501\u2013505. https:\/\/doi.org\/10.1016\/S0009-9236(98)90100-X","journal-title":"Clin Pharmacol Ther"},{"key":"4996_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01245","volume":"9","author":"XX Li","year":"2018","unstructured":"Li XX, Yin J, Tang J, Li Y, Yang Q, Xiao Z, Zhang R, Wang Y, Hong J, Tao L, Xue W, Zhu F (2018) Determining the balance between drug efficacy and safety by the network and biological system profile of its therapeutic target. Front Pharmacol 9:1245. https:\/\/doi.org\/10.3389\/fphar.2018.01245","journal-title":"Front Pharmacol"},{"key":"4996_CR24","volume-title":"Pharmacopoeia of the People\u2019s Republic of China, Part IV, 2015th edn","author":"National Pharmacopoeia Commission","year":"2015","unstructured":"National Pharmacopoeia Commission (2015) Pharmacopoeia of the People\u2019s Republic of China, Part IV, 2015th edn. China Medical Science Press, Beijing"},{"key":"4996_CR25","volume-title":"Pharmacopoeia of the People\u2019s Republic of China, 2025th edn","author":"National Pharmacopoeia Commission","year":"2025","unstructured":"National Pharmacopoeia Commission (2025) Pharmacopoeia of the People\u2019s Republic of China, 2025th edn. China Medical Science Press, Beijing"},{"key":"4996_CR26","unstructured":"NMPA (2016) National Medical Products Administration. Technical Guideline for Human Bioequivalence Studies of Generic Chemical Drugs with Pharmacokinetic Parameters as Endpoints. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20160318210001725.html. Accessed 23 Jun 2025"},{"key":"4996_CR27","unstructured":"NMPA (2020) Announcement on the publication of the Technical Guideline for Bioequivalence Studies of Narrow Therapeutic Index Drugs (No. 62 of 2020). https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/cad15062ff21d6f5b164fa9c562a709e. Accessed 18 Jun 2025"},{"key":"4996_CR28","unstructured":"NMPA (2022) Notification on the publication of the Technical Guideline for Research on Blend Uniformity and In-Process Dose Unit Uniformity of Chemical Oral Solid Dosage Forms. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/ddc61dacf5e355d67f780f5202dde110. Accessed 23 Jun 2025"},{"key":"4996_CR29","unstructured":"PMDA (2012a) Guideline for Bioequivalence Studies for Different Strengths of Oral Solid Dosage Forms. In: English translation of Attachment 2 of Division-Notification 0229 No. 10 of the Pharmaceutical and Food Safety Bureau, dated February 29, 2012. https:\/\/www.nihs.go.jp\/drug\/be-guide(e)\/strength\/GL-E_120229_ganryo.pdf"},{"key":"4996_CR30","unstructured":"PMDA (2012b) Guideline for Bioequivalence Studies of Generic Products. In: English translation of Attachment 1 of Division-Notification 0229 No. 10 of the Pharmaceutical and Food Safety Bureau. https:\/\/www.nihs.go.jp\/drug\/be-guide(e)\/Generic\/GL-E_120229_BE_rev140409.pdf"},{"issue":"12","key":"4996_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3969\/j.issn.1674-2982.2023.12.007","volume":"16","author":"XY Ren","year":"2023","unstructured":"Ren XY, Yan JZ, Ding RL, Shao R (2023) Experience and implications of generic drug substitution promotion policies in foreign countries\u2019 drug use. China Health Policy Res 16(12):49\u201355. https:\/\/doi.org\/10.3969\/j.issn.1674-2982.2023.12.007","journal-title":"China Health Policy Res"},{"key":"4996_CR32","doi-asserted-by":"publisher","unstructured":"Schneider CH, Parambath S, Young JJ, Jain S, Slater H, Sharma S, Kopansky-Giles D, March L, Briggs AM (2022) From Local Action to Global Policy: A Comparative Policy Content Analysis of National Policies to Address Musculoskeletal Health to Inform Global Policy Development. Int J Health Policy Manag :1. https:\/\/doi.org\/10.34172\/ijhpm.2022.7031","DOI":"10.34172\/ijhpm.2022.7031"},{"key":"4996_CR33","unstructured":"SFDA (2005) Notification on the publication of 16 technical guidelines including the Technical Guideline on Stability Studies of Chemical Drugs. https:\/\/www.cde.org.cn\/main\/policy\/view\/f0dbe45e242e85f294f1170128e99176. Accessed 23 Jun 2025"},{"key":"4996_CR34","unstructured":"SFDA (2007) Notification on the publication of 5 technical guidelines including the Technical Guideline on Quality Control of Inhalation Preparations. https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/gzwj\/gzwjyp\/20071023120001509.html. Accessed 23 Jun 2025"},{"key":"4996_CR35","unstructured":"SFDA (2008) Technical Guidelines for Research on Changes in Marketed Chemical Drugs. https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/gzwj\/gzwjyp\/20080515120001217.html. Accessed 23 Jun 2025"},{"key":"4996_CR36","unstructured":"SFDA (2015) Announcement on the publication of the Technical Guideline for Research on Compatibility Between Chemical Drug Injections and Pharmaceutical Glass Containers. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20150728120001551.html. Accessed 23 Jun 2025"},{"key":"4996_CR37","unstructured":"SFDA (2017) Announcement on the publication of the Technical Guidelines for Research on Changes in Chemical Drug Manufacturing Processes. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20170829155101684.html. Accessed 23 Jun 2023"},{"issue":"Suppl 2","key":"4996_CR38","first-page":"1","volume":"41","author":"Shanghai Pharmaceutical Association","year":"2020","unstructured":"Shanghai Pharmaceutical Association (2020) Narrow therapeutic index drugs literature review. Shanghai Pharm 41(Suppl 2):1\u201359","journal-title":"Shanghai Pharm"},{"issue":"8","key":"4996_CR39","doi-asserted-by":"publisher","first-page":"546","DOI":"10.2471\/BLT.17.198002","volume":"95","author":"A Sheikh","year":"2017","unstructured":"Sheikh A, Dhingra-Kumar N, Kelley E, Kieny MP, Donaldson LJ (2017) The third global patient safety challenge: tackling medication-related harm. Bull World Health Organ 95(8):546-546A. https:\/\/doi.org\/10.2471\/BLT.17.198002","journal-title":"Bull World Health Organ"},{"issue":"5","key":"4996_CR40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00228-015-1832-0","volume":"71","author":"J Tamargo","year":"2015","unstructured":"Tamargo J, Le Heuzey J-Y, Mabo P (2015) Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur J Clin Pharmacol 71(5):549\u2013567. https:\/\/doi.org\/10.1007\/s00228-015-1832-0","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"4996_CR41","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1111\/bcp.16098","volume":"91","author":"T van Gelder","year":"2025","unstructured":"van Gelder T, Gelinck A, Meziyerh S, de Vries APJ, Moes DJAR (2025) Therapeutic drug monitoring of tacrolimus after kidney transplantation: trough concentration or area under curve\u2010based monitoring? Br J Clin Pharmacol 91(6):1600\u20131606. https:\/\/doi.org\/10.1111\/bcp.16098","journal-title":"Br J Clin Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-04996-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-04996-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-04996-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:39:41Z","timestamp":1776393581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-04996-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4996"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-04996-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}